VX-765 is the orally available prodrug of a potent and selective competitive inhibitor of ICE/caspase-1 (VRT-043198). VX-765 is currently under clinical development for the treatment of inflammatory and autoimmune conditions, as it blocks the hypersensitive response to an inflammatory stimulus.
Investigated for use/treatment in inflammatory disorders (unspecified) and psoriasis and psoriatic disorders.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.